These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 12637489)

  • 1. Adjuvant chemotherapy for node-positive breast cancer patients: which is the reference today?
    Fumoleau P; Bonneterre J; Luporsi E
    J Clin Oncol; 2003 Mar; 21(6):1190-1; author reply 1191-2. PubMed ID: 12637489
    [No Abstract]   [Full Text] [Related]  

  • 2. [Docetaxel in the adjuvant treatment of operable breast carcinoma. News from ASCO 2002].
    Montemurro F
    Tumori; 2002; 88(4):A1-7. PubMed ID: 12402832
    [No Abstract]   [Full Text] [Related]  

  • 3. Fluorouracil, doxorubicin, and cyclophosphamide (FAC) versus FAC followed by weekly paclitaxel as adjuvant therapy for high-risk, node-negative breast cancer: results from the GEICAM/2003-02 study.
    Martín M; Ruiz A; Ruiz Borrego M; Barnadas A; González S; Calvo L; Margelí Vila M; Antón A; Rodríguez-Lescure A; Seguí-Palmer MA; Muñoz-Mateu M; Dorca Ribugent J; López-Vega JM; Jara C; Espinosa E; Mendiola Fernández C; Andrés R; Ribelles N; Plazaola A; Sánchez-Rovira P; Salvador Bofill J; Crespo C; Carabantes FJ; Servitja S; Chacón JI; Rodríguez CA; Hernando B; Álvarez I; Carrasco E; Lluch A
    J Clin Oncol; 2013 Jul; 31(20):2593-9. PubMed ID: 23733779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are anthracycline-taxane regimens the new standard of care in the treatment of metastatic breast cancer?
    Valero V; Hortobagyi GN
    J Clin Oncol; 2003 Mar; 21(6):959-62. PubMed ID: 12637456
    [No Abstract]   [Full Text] [Related]  

  • 5. Docetaxel in combination with doxorubicin and cyclophosphamide as adjuvant treatment for early node-positive breast cancer: a cost-effectiveness and cost-utility analysis.
    Wolowacz SE; Cameron DA; Tate HC; Bagust A
    J Clin Oncol; 2008 Feb; 26(6):925-33. PubMed ID: 18281666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 3-year results of docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer: a pilot study.
    Ferreira Filho AF; Crown J; Cardoso F; Nogaret JM; Duffy K; Dolci S; Rowan S; O'Higgins N; Batter V; Paesmans M; Piccart MJ; Di Leo A
    Anticancer Res; 2002; 22(4):2471-6. PubMed ID: 12174946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
    Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
    J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer.
    Pierga JY; Mouret E; Diéras V; Laurence V; Beuzeboc P; Dorval T; Palangié T; Jouve M; Vincent-Salomon A; Scholl S; Extra JM; Asselain B; Pouillart P
    Br J Cancer; 2000 Dec; 83(11):1480-7. PubMed ID: 11076657
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
    Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
    J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
    Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Impact of taxanes in the adjuvant setting of node-negative breast cancers].
    Lagha A; Chraiet N; Labidi S; Krimi S; Ayadi M; Gligorov J; Boussen H
    Bull Cancer; 2013 May; 100(5):465-71. PubMed ID: 23613145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimal chemotherapy for women with breast cancer: the plot thickens.
    Pater JL; Pritchard KI
    J Clin Oncol; 2003 Mar; 21(6):963-4. PubMed ID: 12637457
    [No Abstract]   [Full Text] [Related]  

  • 13. [Hungarian experience with docetaxel combination (TAC) in the adjuvant treatment of breast cancer. Results of BCIRG 001 randomized, multicentric, phase III trial].
    Boér K; Láng I; Juhos E; Pintér T; Szántó J
    Magy Onkol; 2003; 47(2):141-8. PubMed ID: 12975660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose-dense treatment prolongs disease-free survival of women with node positive breast cancer.
    Dang C; Seidman AD
    Cancer Treat Rev; 2003 Oct; 29(5):453-6. PubMed ID: 12972365
    [No Abstract]   [Full Text] [Related]  

  • 15. BCIRG 001 molecular analysis: prognostic factors in node-positive breast cancer patients receiving adjuvant chemotherapy.
    Dumontet C; Krajewska M; Treilleux I; Mackey JR; Martin M; Rupin M; Lafanechère L; Reed JC
    Clin Cancer Res; 2010 Aug; 16(15):3988-97. PubMed ID: 20576719
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A randomized controlled study comparing uracil-tegafur (UFT)+tamoxifen (UFT+TAM therapy) with cyclophosphamide+adriamycin+5-fluorouracil (CAF therapy) for women with stage I , II, or IIIa breast cancer with four or more involved nodes in the adjuvant setting].
    Inaji H; Sakai K; Oka T; Ozawa K; Saito Y; Senoo T; Taguchi T; Terasawa T; Nakao K; Mori T; Koyama H; Oshima A
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1423-9. PubMed ID: 17033231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant docetaxel for node-positive breast cancer.
    Martin M; Pienkowski T; Mackey J; Pawlicki M; Guastalla JP; Weaver C; Tomiak E; Al-Tweigeri T; Chap L; Juhos E; Guevin R; Howell A; Fornander T; Hainsworth J; Coleman R; Vinholes J; Modiano M; Pinter T; Tang SC; Colwell B; Prady C; Provencher L; Walde D; Rodriguez-Lescure A; Hugh J; Loret C; Rupin M; Blitz S; Jacobs P; Murawsky M; Riva A; Vogel C;
    N Engl J Med; 2005 Jun; 352(22):2302-13. PubMed ID: 15930421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of axillary lymph node-negative, estrogen receptor-negative breast cancer: updated findings from National Surgical Adjuvant Breast and Bowel Project clinical trials.
    Fisher B; Jeong JH; Anderson S; Wolmark N
    J Natl Cancer Inst; 2004 Dec; 96(24):1823-31. PubMed ID: 15601638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose density in breast cancer: a simple message?
    Lin NU; Gelman R; Winer EP
    J Natl Cancer Inst; 2005 Dec; 97(23):1712-4. PubMed ID: 16333021
    [No Abstract]   [Full Text] [Related]  

  • 20. Dose-dense paclitaxel versus docetaxel following FEC as adjuvant chemotherapy in axillary node-positive early breast cancer: a multicenter randomized study of the Hellenic Oncology Research Group (HORG).
    Saloustros E; Malamos N; Boukovinas I; Kakolyris S; Kouroussis C; Athanasiadis A; Ziras N; Kentepozidis N; Makrantonakis P; Polyzos A; Christophyllakis C; Georgoulias V; Mavroudis D
    Breast Cancer Res Treat; 2014 Dec; 148(3):591-7. PubMed ID: 25399229
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.